About Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals is primarily engaged in the business of development, manufacturing and marketing of pharmaceutical products. The Company's research and development facilities are located at Mahape, Sinnar and Taloja and manufacturing facilities a
Founded
1977
CEO
Glenn Saldanha
Employees
17,782
HQ
Mumbai, India
Finished Products
1Sales
₹39,902.52Cr2Other Operating Income
₹1,204.32Cr3Services
₹160.30CrRaw Materials
1Raw Material Consumed
₹2,775.58Cr29 (Dicaboxylic Acid)
₹2,715.79Cr3Purchases of Traded Goods
₹782.00Cr4Stores and Spares
₹65.66CrAbout Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals is primarily engaged in the business of development, manufacturing and marketing of pharmaceutical products. The Company's research and development facilities are located at Mahape, Sinnar and Taloja and manufacturing facilities a
Founded:1977
CEO:Glenn Saldanha
Employees:17,782
HQ:Mumbai, India
Finished Products
1Sales
₹39,902.52Cr2Other Operating Income
₹1,204.32Cr3Services
₹160.30CrRaw Materials
1Raw Material Consumed
₹2,775.58Cr29 (Dicaboxylic Acid)
₹2,715.79Cr3Purchases of Traded Goods
₹782.00Cr4Stores and Spares
₹65.66CrPrice Performance & Market EventsPrice Performance
Loading chart data…
Key Metrics
Trading & valuation snapshot
52W High
₹2,538
52W Low
₹1,793
Volume516.03K
Avg VolumeN/A
Beta0.87
Dividend Yield0.20%
Key Financial Ratios
Profitability, leverage & efficiency at a glance
P/E Ratio
38.49x
Valuation
P/B Ratio
6.58x
Valuation
EPS
₹63.70
Valuation
Dividend Yield
0.20%
Valuation
ROE
28.08%
Profitability
ROCE
32.70%
Profitability
Revenue by Segment
Contribution & growth by business line
Pharmaceutical ProductsRevenue split N/A
Geographical Revenue Split
Domestic vs international exposure
Domestic
21.9%
International
78.1%
North America42.0%
India21.9%
Europe18.7%
Latin America and Rest of the World17.3%
Strategic Relations
Collaborations, joint ventures & subsidiaries
No collaborations data available.
Forensic Metrics
Financial health & earnings-quality indicators
Revenue Quality
N/A
Days Sales Outstanding
Leverage
0.06x
Debt-to-Equity
Earnings Quality
N/A
Cash Conversion Ratio
Efficiency
N/A
Asset Turnover
Earnings Quality
N/A
Accruals Ratio
Profitability
N/A
Gross Margin
Growth
12.9%
Sales Growth
These metrics are derived from available financial disclosures and market data. Use them together with company filings and qualitative analysis before making decisions.